Erythrocyte–antibody conjugates to overcome immunotherapy resistance

Urvashi Mitbander Joshi; Rodabe N. Amaria

doi:10.1038/s43018-025-01105-y

Erythrocyte–antibody conjugates to overcome immunotherapy resistance

Melanoma Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte–antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape anti-tumor immune responses, with promising safety and efficacy data from a phase 1 trial in patients with advanced anti-PD-1-resistant solid tumors.

Original language	English (US)
Pages (from-to)	562-564
Number of pages	3
Journal	Nature Cancer
Volume	7
Issue number	4
DOIs	https://doi.org/10.1038/s43018-025-01105-y
State	Published - Apr 2026

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-025-01105-y

Cite this

@article{bc7595e0bbb74ea6adbbbf6f4381f147,

title = "Erythrocyte{\textendash}antibody conjugates to overcome immunotherapy resistance",

abstract = "Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte{\textendash}antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape anti-tumor immune responses, with promising safety and efficacy data from a phase 1 trial in patients with advanced anti-PD-1-resistant solid tumors.",

author = "Joshi, \{Urvashi Mitbander\} and Amaria, \{Rodabe N.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc 2026.",

year = "2026",

month = apr,

doi = "10.1038/s43018-025-01105-y",

language = "English (US)",

volume = "7",

pages = "562--564",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "4",

}

TY - JOUR

T1 - Erythrocyte–antibody conjugates to overcome immunotherapy resistance

AU - Joshi, Urvashi Mitbander

AU - Amaria, Rodabe N.

N1 - Publisher Copyright: © Springer Nature America, Inc 2026.

PY - 2026/4

Y1 - 2026/4

N2 - Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte–antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape anti-tumor immune responses, with promising safety and efficacy data from a phase 1 trial in patients with advanced anti-PD-1-resistant solid tumors.

AB - Strategies are needed to overcome resistance to immune checkpoint inhibitors in patients with cancer. An erythrocyte–antibody conjugate for the delivery of anti-PD-1 is now shown to favorably reshape anti-tumor immune responses, with promising safety and efficacy data from a phase 1 trial in patients with advanced anti-PD-1-resistant solid tumors.

UR - https://www.scopus.com/pages/publications/105030668369

UR - https://www.scopus.com/pages/publications/105030668369#tab=citedBy

U2 - 10.1038/s43018-025-01105-y

DO - 10.1038/s43018-025-01105-y

M3 - Comment/debate

C2 - 41721137

AN - SCOPUS:105030668369

SN - 2662-1347

VL - 7

SP - 562

EP - 564

JO - Nature Cancer

JF - Nature Cancer

IS - 4

ER -

Erythrocyte–antibody conjugates to overcome immunotherapy resistance

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this